These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

44 related articles for article (PubMed ID: 7841429)

  • 21. Effect of drug type on the degradation rate of PLGA matrices.
    Siegel SJ; Kahn JB; Metzger K; Winey KI; Werner K; Dan N
    Eur J Pharm Biopharm; 2006 Nov; 64(3):287-93. PubMed ID: 16949804
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of an animal model to assess the immunogenicity of single-dose tetanus and diphtheria vaccines based on controlled release from biodegradable polymer microspheres.
    Gupta RK; Griffin P; Rivera R; Siber GR
    Dev Biol Stand; 1998; 92():277-87. PubMed ID: 9554282
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antitumor efficacy and local distribution of doxorubicin via intratumoral delivery from polymer millirods.
    Weinberg BD; Ai H; Blanco E; Anderson JM; Gao J
    J Biomed Mater Res A; 2007 Apr; 81(1):161-70. PubMed ID: 17120197
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro elution of vancomycin/amikacin/steroid from solvent-free biodegradable scleral plugs.
    Liu SJ; Kau YC; Liaw CW; Peng YJ
    Int J Pharm; 2009 Mar; 370(1-2):75-80. PubMed ID: 19101617
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Controlled release of levonorgestrel from biodegradable poly(D,L-lactide-co-glycolide) microspheres: in vitro and in vivo studies.
    Wang SH; Zhang LC; Lin F; Sa XY; Zuo JB; Shao QX; Chen GS; Zeng S
    Int J Pharm; 2005 Sep; 301(1-2):217-25. PubMed ID: 16040213
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Size and temperature effects on poly(lactic-co-glycolic acid) degradation and microreservoir device performance.
    Grayson AC; Cima MJ; Langer R
    Biomaterials; 2005 May; 26(14):2137-45. PubMed ID: 15576189
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-performance liquid chromatographic analysis of isoniazid and acetylisoniazid in biological fluids.
    Hutchings A; Monie RD; Spragg B; Routledge PA
    J Chromatogr; 1983 Oct; 277():385-90. PubMed ID: 6643626
    [No Abstract]   [Full Text] [Related]  

  • 28. Nanomedicines as Drug Delivery Carriers of Anti-Tubercular Drugs: From Pathogenesis to Infection Control.
    Hussain A; Singh S; Das SS; Anjireddy K; Karpagam S; Shakeel F
    Curr Drug Deliv; 2019; 16(5):400-429. PubMed ID: 30714523
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel drug delivery systems: desired feat for tuberculosis.
    Kaur K; Gupta A; Narang RK; Murthy RS
    J Adv Pharm Technol Res; 2010 Apr; 1(2):145-63. PubMed ID: 22247841
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tuberculosis chemotherapy: current drug delivery approaches.
    du Toit LC; Pillay V; Danckwerts MP
    Respir Res; 2006 Sep; 7(1):118. PubMed ID: 16984627
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro and in vivo evaluations of biodegradable implants for hormone replacement therapy: effect of system design and PK-PD relationship.
    Lin S; Chao PY; Chien YW; Sayani S; Kuma S; Mason M; Wes T; Yang A; Monkhouse D
    AAPS PharmSciTech; 2001 Sep; 2(3):E16. PubMed ID: 14727875
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemotherapeutic potential of orally administered poly(lactide-co-glycolide) microparticles containing isoniazid, rifampin, and pyrazinamide against experimental tuberculosis.
    Ul-Ain Q; Sharma S; Khuller GK
    Antimicrob Agents Chemother; 2003 Sep; 47(9):3005-7. PubMed ID: 12937014
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic efficacy of Poly(DL-lactide-Co-Glycolide)-encapsulated antitubercular drugs against Mycobacterium tuberculosis infection induced in mice.
    Dutt M; Khuller GK
    Antimicrob Agents Chemother; 2001 Jan; 45(1):363-6. PubMed ID: 11121000
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sustained release of isoniazid in vivo from a single implant of a biodegradable polymer.
    Gangadharam PR; Ashtekar DR; Farhi DC; Wise DL
    Tubercle; 1991 Jun; 72(2):115-22. PubMed ID: 1949214
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Experimental chemotherapy of tuberculosis using single dose treatment with isoniazid in biodegradable polymers.
    Gangadharam PR; Kailasam S; Srinivasan S; Wise DL
    J Antimicrob Chemother; 1994 Feb; 33(2):265-71. PubMed ID: 8182007
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biodegradable implants from poly-(alpha-hydroxy acid) polymers for isoniazid delivery.
    Hurley L; Andersen BR
    Int J Tuberc Lung Dis; 1999 Nov; 3(11):1015-24. PubMed ID: 10587324
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Maintenance of therapeutically active levels of isoniazid for prolonged periods in rabbits after a single implant of biodegradable polymer.
    Kailasam S; Daneluzzi D; Gangadharam PR
    Tuber Lung Dis; 1994 Oct; 75(5):361-5. PubMed ID: 7841429
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemotherapy of tuberculosis in mice using single implants of isoniazid and pyrazinamide.
    Gangadharam PR; Geeta N; Hsu YY; Wise DL
    Int J Tuberc Lung Dis; 1999 Jun; 3(6):515-20. PubMed ID: 10383065
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.